Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 2/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.30 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27412736 | 0.82 | AKT2 (0.38) | MAP4K1AKT2AKT1CHEK1DPP4 | |
| SCHEMBL6202858 | 0.77 | METAP2 (0.31) | MAP4K1DPP4 | |
| SCHEMBL6202767 | 0.77 | MDM2 (0.43) | MAP4K1DPP4 | |
| SCHEMBL6052010 | 0.74 | HDAC4 (0.39) | MAP4K1AKT2AKT1CHEK1DPP4 | |
| SCHEMBL6205377 | 0.74 | NISCH (0.49) | DPP4CLK2CLK4 | |
| SCHEMBL29110764 | 0.73 | — | — | |
| SCHEMBL9171828 | 0.73 | HDAC4 (0.38) | MAP4K1AKT2AKT1CHEK1DPP4 | |
| SCHEMBL5612694 | 0.71 | METAP2 (0.37) | MAP4K1AKT2AKT1DPP4CLK4 | |
| SCHEMBL26677406 | 0.71 | AKT2 (0.41) | MAP4K1AKT2AKT1CHEK1DPP4 | |
| SCHEMBL5796400 | 0.70 | GRM5 (0.36) | PIM1CLK2DYRK2CLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1247810-B1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER PROD INC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6664395-B2 | Benzotriazole compoundsn are the potent inhibitors of MAP kinases, preferably p38 kinase. They are useful for treating inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion, ischemia | PFIZER INC | 2003-12-16 | — | — | US | disclosed |
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-1247810-A1 | Novel benzotriazoles anti-inflammatory compounds | Pfizer Products Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078432-A1 | Novel benzotriazoles anti-inflammatory compounds | MAPK1, JAK1, RUNX1 | MAP4K1 126/4885AKT2 384/4885AKT1 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.